CARRIE KRAMER: Open Payments
NPI 1881389328 · SYRACUSE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,022 in 54 payments from 11 companies in 2025. Trend: 2023 $1,240 · 2024 $2,411 · 2025 $1,022
Food & beverage: $1,022
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $220 |
| Teva Pharmaceuticals USA, Inc. | 10 | $214 |
| ABBVIE INC. | 8 | $138 |
| Otsuka America Pharmaceutical, Inc. | 4 | $109 |
| Alkermes, Inc. | 3 | $82 |
| Vanda Pharmaceuticals Inc. | 2 | $78 |
| Neurocrine BioSciences, Inc. | 3 | $75 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Biogen, Inc. | 1 | $22 |
Products named: CAPLYTA, AUSTEDO XR, VRAYLAR, REXULTI, ARISTADA, HETLIOZ, INGREZZA, UZEDY.
Industry payments across NY — which companies pay providers there.
